Review article. Buprenorphine in the workers' compensation setting

Stephen Colameco, MD, MEd, FASAM; Mel Pohl, MD, FASAM

doi:10.5055/jom.2014.0215

Authors

Stephen Colameco, MD, MEd, FASAM
Mel Pohl, MD, FASAM

DOI:

https://doi.org/10.5055/jom.2014.0215

Keywords:

buprenorphine, workers' compensation, chronic pain, opioid dependence

Abstract

Buprenorphine is approved by the Food and Drug Administration for the treatment of chronic pain in low-dose transdermal patch formulations and for the treatment of addiction in high-dose sublingual tablets and films. Clinicians often prescribe these high-dose preparations “off label” for pain management. In the workers' compensation setting, it is particularly important to consider factors such as a) if the injured person has, and is being treated for co-occurring addiction as well as pain; b) if alternative therapies, including opioid withdrawal, were considered prior to initiating buprenorphine treatment; and c) the anticipated duration of treatment. This article reviews buprenorphine's approved indications, formulations, pharmacology, clinical efficacy, and special considerations in the workers' compensation setting.

Author Biographies

Stephen Colameco, MD, MEd, FASAM

Family Medicine, Rowan University School of Osteopathic Medicine, Stratford, New Jersey.

Mel Pohl, MD, FASAM

Medical Director, Las Vegas Recovery Center, Las Vegas, Nevada.

References

Purdue Pharma L.P.: Butrans Prescribing Information. 2013. Available at http:/butrans.com. Accessed October 10, 2013.

Pergolizzi J, Aloisi AM, Dahan A, et al.: Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract. 2010; 10(5): 428-450. DOI: https://doi.org/10.1111/j.1533-2500.2010.00378.x

Huang P, Kehner GB, Cowan A, et al.: Comparison of pharmacological activities of buprenorphine and norbuprenorphine: Norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther. 2001; 297(2): 688-695.

Center for Substance Abuse Treatment: Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2004. Treatment Improvement Protocol (TIP) Series, No. 40. 2 Pharmacology. Available at http://www.ncbi.nlm.nih.gov/books/NBK64236. Accessed October 10, 2013.

Whelan PJ, Remski K: Buprenorphine vs methadone treatment: A review of evidence in both developed and developing worlds. J Neurosci Rural Pract. 2012; 3(1): 45-50. DOI: https://doi.org/10.4103/0976-3147.91934

IMS Health: Top 100 Drugs for 2012. Available at http://www.drugs.com/stats/top100/2012/q1/sales. Accessed October 12, 2013.

Reckitt Benckiser Pharmaceuticals: Suboxone Film Dosing Guidance. Available at http://www.suboxone.com/content/pdfs/SuboxonePI.pdf. Accessed October 12, 2013.

Orexo US: Zubsolv Prescribing Information. Available at http://www.zubsolv.com/pdf/zubsolvFullPI-patient.pdf#1. Accessed November 26, 2013.

Suboxone: Amazing detox tool monster maintenance drug. Available at http://guineveregetssober.com/suboxone-amazingdetox-tool-monster-maintenance-drug/. Accessed October 11, 2013.

Suboxone taper. Available at http://suboxonetaper.com/suboxone-taper/. Accessed October 11, 2013.

Suboxone friend or foe? Available at http://serenityhelp.com/addiction-information/suboxone-friend-or-foe/. Accessed October 11, 2013.

Knoff A: Field debates pros and cons of Suboxone taper using film. Available at http://www.alcoholismdrugabuseweekly.com/Article-Detail/field-debates-pros-and-cons-of-suboxonetaper-using-film.aspx. Accessed October 11, 2013.

New Mexico Behavioral Health Collaborative: New Mexico Treatment Guidelines for Medical Providers Who Treat Opioid Addiction Using Buprenorphine. 2012. Available at http://www.bhc.state.nm.us/pdf/NMbuprenorphinetreatguidelinesAug12.pdf. Accessed October 15, 2013.

Weiss RD, Potter JS, Fiellin DA, et al.: Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: A 2-phase randomized controlled trial. Arch Gen Psychiatry. 2011; 68(12): 1238-1246. DOI: https://doi.org/10.1001/archgenpsychiatry.2011.121

Hamza H, Bryson EO: Buprenorphine maintenance therapy in opioid-addicted health care professionals returning to clinical practice: A hidden controversy. Mayo Clin Proc. 2012; 87(3): 260-267. DOI: https://doi.org/10.1016/j.mayocp.2011.09.007

DuPont RL, McLellan AT, Carr G, et al.: How are addicted physicians treated?: A national survey of Physician Health Programs. J Subst Abuse Treat. 2009; 37(1): 1-7. DOI: https://doi.org/10.1016/j.jsat.2009.03.010

McLellan AT, Skipper GS, Campbell M, et al.: Five year outcomes in a cohort study of physicians treated for substance use disorders in the United States. BMJ. 2008; 337: a2038. DOI: https://doi.org/10.1136/bmj.a2038

McPherson ML: Demystifying Opioid Conversion Calculations: A Guide to Effective Dosing. Bethesda, MD: American Society of Health-System Pharmacists, 2011: 200 pp (softbound, ISBN: 9781585281985).

Cowan A: Buprenorphine: The basic pharmacology revisited. J Addict Med. 2007; 1(2): 68-72. DOI: https://doi.org/10.1097/ADM.0b013e31806c9202

Greenwald MK, Johanson CE, Moody DE, et al.: Effects of buprenorphine maintenance dose on μ-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology. 2003; 28: 2000-2009. DOI: https://doi.org/10.1038/sj.npp.1300251

Rosen K, Gutierrez A, Haller D, et al.: Sublingual buprenorphine for chronic pain: A survey of clinician prescribing practices. Clin J Pain. 2014; 30(4): 295-300. DOI: https://doi.org/10.1097/AJP.0b013e318298ddad

Chaparro LE, Furlan AD, Deshpande A, et al.: Opioids compared to placebo or other treatments for chronic low-back pain. Cochrane Database Syst Rev. 2013; 8: CD004959. DOI: https://doi.org/10.1002/14651858.CD004959.pub4

Dana T: Long-Acting Opioid Analgesics Single Drug Addendum: Transdermal Tuprenorphine (Butrans). Pacific Northwest Evidence-based Practice Center. Oregon Health & Science University.

Malinoff HL, Barkin RL, Wilson G: Sublingual buprenorphine is effective in the treatment of chronic pain syndrome. Am J Ther. 2005; 12(5): 379-384. DOI: https://doi.org/10.1097/01.mjt.0000160935.62883.ff

Roux P, Sullivan MA, Cohen J, et al.: Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: Reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone. Pain. 2013; 154(8): 1442-1448. DOI: https://doi.org/10.1016/j.pain.2013.05.004

Neumann AM, Blondell RD, Jaanimägi U, et al.: A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction. J Addict Dis. 2013; 32(1): 68-78. DOI: https://doi.org/10.1080/10550887.2012.759872

Daitch J, Frey ME, Silver D, et al.: Conversion of chronic pain patients from full-opioid agonists to sublingual buprenorphine. Pain Physician. 2012; 15(3 Suppl): ES59-ES66. DOI: https://doi.org/10.36076/ppj.2012/15/ES59

Jones JD, Sullivan MA, Manubay J, et al.: The subjective, reinforcing, and analgesic effects of oxycodone in patients with chronic, non-malignant pain who are maintained on sublingual buprenorphine/naloxone. Neuropsychopharmacology. 2011; 36(2): 411-422. DOI: https://doi.org/10.1038/npp.2010.172

Bohnert AS, Valenstein M, Bair MJ, et al.: Association between opioid prescribing patterns and opioid overdoserelated deaths. JAMA. 2011; 305: 1315-1321. DOI: https://doi.org/10.1001/jama.2011.370

Dunn KM, Saunders KW, Rutter CM, et al.: Opioid prescriptions for chronic pain and overdose: A cohort study. Ann Intern Med. 2010; 152: 85-92. DOI: https://doi.org/10.7326/0003-4819-152-2-201001190-00006

Gomes T, Mamdani MM, Dhalla IA, et al.: Opioid dose and drug-related mortality in patients with nonmalignant pain. Arch Intern Med. 2011; 171: 686-691. DOI: https://doi.org/10.1001/archinternmed.2011.117

Chou R, Fanciullo GJ, Fine PG, et al.: American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009; 10(2): 113-130. DOI: https://doi.org/10.1016/j.jpain.2008.10.008

Federation of State Medical Boards: Model policy for the use of controlled substances for the treatment of pain. J Pain Palliat Care Pharmacother. 2004; 19: 73-78. DOI: https://doi.org/10.1080/J354v19n02_14

Washington State Department of Labor and Industries: Guideline for Prescribing Opioids to Treat Pain in Injured Workers. 2013. Available at http://www.lni.wa.gov/ClaimsIns/Providers/TreatingPatients/ByCondition/Opioids/default.asp. Accessed November 26, 2013.

Baron MJ, McDonald PW: Significant pain reduction in chronic pain patients after detoxification from high-dose opioids. J Opioid Manag. 2006; 2(5): 277-282. DOI: https://doi.org/10.5055/jom.2006.0041

Rome JD, Townsend CO, Bruce BK, et al.: Chronic noncancer pain rehabilitation with opioid withdrawal: Comparison of treatment outcomes based on opioid use status at admission. Mayo Clin Proc. 2004; 79(6): 759-768. DOI: https://doi.org/10.1016/S0025-6196(11)62628-1

Townsend CO, Kerkvliet JL, Bruce BK, et al.: A longitudinal study of the efficacy of a comprehensive pain rehabilitation program with opioid withdrawal: Comparison of treatment outcomes based on opioid use status at admission. Am J Phys Med Rehabil. 2008; 87(7): 527-536. DOI: https://doi.org/10.1016/j.pain.2008.08.005

Crisostomo RA, Schmidt JE, Hooten WM, et al.: Withdrawal of analgesic medication for chronic low-back pain patients: Improvement in outcomes of multidisciplinary rehabilitation regardless of surgical history. Am J Phys Med Rehabil. 2008; 87(7): 527-536. DOI: https://doi.org/10.1097/PHM.0b013e31817c124f